Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Davis
- Full Time Employees
- 75,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Merck & Co., Inc. $MRK Shares Bought by Argent Capital Management LLC
Merck & Co., Inc. $MRK Position Boosted by Arete Wealth Advisors LLC
Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
Merck Announces Fourth-Quarter 2026 Dividend
Merck Announces Fourth-Quarter 2026 Dividend
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Merck & Co., Inc. $MRK Shares Purchased by Arete Wealth Advisors LLC
Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
Brokerages Set Merck & Co., Inc. (NYSE:MRK) Target Price at $133.94
Bollard Group LLC Acquires 6,691 Shares of Merck & Co., Inc. $MRK
Merck licenses experimental HIV pill to generic makers in 129 countries
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
Bank of Nova Scotia Reduces Position in Merck & Co., Inc. $MRK
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
Why Retirees Are Choosing This $100.8 Billion ETF Over Individual Dividend Stocks
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
Merck & Co., Inc. $MRK Shares Sold by Acumen Wealth Advisors LLC